Project Grant HT94252310670
Award Date 9/1/23
Completion Date 8/31/26
Dollars Obligated $1.2M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
- This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,158,989.00 to Yale University to conduct research on optimizing adoptive cellular immunotherapy for rare melanomas. The research project commenced on September 1, 2023 and is scheduled for completion by August 31, 2026. The key objectives of this grant-funded research are to advance innovative medical solutions for rare forms of melanoma that are difficult to...
- The U.S. Department of Defense's Defense Health Agency awarded a $1,235,447 Project Grant to Yale University on July 1, 2023. This 3-year grant, funded under the Military Medical Research and Development program (CFDA 12.420), will support research targeting the chromatin regulator WDR5 to treat breast cancer metastasis. The project aims to transform health care for service members and the general public through innovative and impactful biomedical research investigating medical solutions for the...
- The Defense Health Agency awarded Yale University a 3-year, USD 1,277,053 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to target the chromatin regulator WDR5 to treat breast cancer metastasis. The project aims to advance the understanding and development of novel therapeutic approaches for breast cancer, a leading cause of cancer-related deaths. As the prime awardee, Yale University will conduct the research, development, and testing activities...
- The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...
- Federal Project Grant Award Summary Yale University received a $1,009,054 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2029. The award supports research focused on the discovery and therapeutic targeting of endogenous retroviruses in clear cell renal cell carcinoma. This biomedical research initiative addresses cancer treatment through investigation of endogenous...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
- The U.S. Department of Defense, through its Military Medical Research and Development program (CFDA 12.420), awarded a $460,279 Project Grant to Yale University on February 15, 2025. The grant supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research project, titled "LOSS OF PROTEOSTASIS AND VASCULAR AMYLOIDOSIS," focuses on investigating medical solutions for the battlefield and developing...
- The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
- Federal Grant Award Summary Yale University received a $670,917 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 15, 2025, through June 14, 2027. The award supports research titled "Exploiting METTL3 Inhibition-Induced Dysregulation of DNA Repair in the Treatment of Leukemia," conducted at Yale's Hamden, Connecticut location. This research project investigates novel therapeutic...